HomeLatest NewsLowe's and Zoom Stock Surge; Unity Software Declines

Lowe’s and Zoom Stock Surge; Unity Software Declines

Stock Market Update: Key Movers and Shakers

Lowe’s Leads the Way

Lowe’s stock saw a 3% rise despite a slowdown in home improvement spending. The retailer’s fourth-quarter net sales exceeded expectations, showcasing resilience in challenging times.

Macy’s Turnaround Plan

Macy’s stock climbed 3.5% as the company announced plans to close 150 stores by 2026. Despite weaker demand for apparel and shoes, the retailer remains optimistic about its future.

- Advertisement -

Zooming Ahead

Zoom stock surged 5.5% after reporting strong fourth-quarter results. The video-conferencing software provider capitalized on the increased demand for its products in a world embracing hybrid work models.

Workday’s Mixed Results

Workday stock dipped 2% despite beating profit expectations. The cloud-based HR software provider faced revenue challenges but remains steady in its full-year forecast.

Unity Software Stumbles

Unity Software stock plummeted 9% due to a disappointing revenue forecast. The company’s strategic shift in revenue guidance impacted investor confidence.

- Advertisement -

CarGurus’ Rollercoaster Ride

CarGurus stock fell 7% after reporting mixed fourth-quarter earnings and a weak first-quarter guidance. The online auto marketplace faces uncertainties in the market.

Hims Hers Health Takes Off

Hims Hers Health stock skyrocketed 30% on positive net income projections for 2024. The telehealth company anticipates robust sales, signaling a promising year ahead.

Intuitive Machines’ Lunar Setback

Intuitive Machines stock plunged 15% following challenges in its lunar mission. Communication issues and solar charging problems marred the space exploration company’s progress.

AutoZone Drives Forward

AutoZone stock surged over 5.5% on stellar earnings and revenue reports. The auto parts retailer’s growth trajectory remains strong, despite slight misses in sales expectations.

Viking Therapeutics’ Triumph

Viking Therapeutics shares surged more than 80% after positive Phase 2 trial results for obesity drug VK2735. The company’s breakthrough signals potential in the pharmaceutical sector.

Additional reporting by Louis Juricic

Must Read

Advertisement

spot_imgspot_img